Literature DB >> 12429643

Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.

Raffit Hassan1, Megan R Lerner, Doris Benbrook, Stan A Lightfoot, Daniel J Brackett, Qing-Cheng Wang, Ira Pastan.   

Abstract

PURPOSE: Mesothelin, a cell surface glycoprotein overexpressed in ovarian cancer, mesotheliomas, and some squamous cell carcinomas, is an attractive candidate for targeted therapy because it is not shed in significant amounts into the bloodstream and is not present in significant amounts on normal human tissues except for mesothelial cells. The objective of this study was to determine the antitumor activity of SS1(dsFv)PE38, a recombinant antimesothelin immunotoxin, against human gynecologic tumors grown in short-term culture in vitro. EXPERIMENTAL
DESIGN: Tumor cells obtained from primary cultures of five ovarian and one cervical tumor were mixed with an equal proportion of NIH-3T3 fibroblasts and plated inside collagen gels in tissue culture plates. After 4-7 days of growth, these organotypic cultures were treated with media alone, SS1(dsFv)PE38, and a control immunotoxin RFB4(dsFv)PE38, which targets the CD22 antigen not present on gynecologic tumors, every other day x 3. The organotypic culture gels were then formalin fixed, paraffin embedded, and evaluated for immunotoxin sensitivity using light microscopic examination of H&E-stained slides and also evaluated for apoptosis using the terminal deoxynucleotidyl transferase-mediated nick end labeling assay.
RESULTS: Tumors expressing mesothelin showed a significant dose-dependent sensitivity to SS1(dsFv)PE38 even at concentrations as low as 1 ng/ml, whereas no antitumor activity was seen at 100 ng/ml in tumors that did not express mesothelin. This activity was specifically attributable to mesothelin targeting because RFB4 (dsFv)-PE38 had no activity against mesothelin-expressing tumors.
CONCLUSIONS: These results demonstrate that ovarian and cervical tumor cells obtained from patients can be grown in short-term culture using an organotypic culture model. Our results also show low concentrations of an immunotoxin targeting mesothelin is cytotoxic to mesothelin-expressing human tumors by inducing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429643

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 2.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

3.  Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Authors:  Elliot L Servais; Christos Colovos; Luis Rodriguez; Adam J Bograd; Jun-ichi Nitadori; Camelia Sima; Valerie W Rusch; Michel Sadelain; Prasad S Adusumilli
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

4.  Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.

Authors:  Junko Yokokawa; Claudia Palena; Philip Arlen; Raffit Hassan; Mitchell Ho; Ira Pastan; Jeffrey Schlom; Kwong Y Tsang
Journal:  Clin Cancer Res       Date:  2005-09-01       Impact factor: 12.531

5.  ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.

Authors:  Roberta Traini; Gal Ben-Josef; Diana V Pastrana; Elizabeth Moskatel; Ashima K Sharma; Antonella Antignani; David J Fitzgerald
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

Review 6.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

7.  T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Authors:  Marcela V Maus; Andrew R Haas; Gregory L Beatty; Steven M Albelda; Bruce L Levine; Xiaojun Liu; Yangbing Zhao; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

Review 8.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

9.  Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.

Authors:  Xiufen Liu; Fabian Müller; Alan S Wayne; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

Review 10.  Mesothelin targeted cancer immunotherapy.

Authors:  Raffit Hassan; Mitchell Ho
Journal:  Eur J Cancer       Date:  2007-10-22       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.